Anzeige
Mehr »
Login
Samstag, 05.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
403 Leser
Artikel bewerten:
(2)

Global Genomics Market to Reach $68 Billion by 2030: P&S Intelligence

NEW YORK, Sept. 8, 2020 /PRNewswire/ -- Being consistently benefitted by government support, the global genomics market is expected to cross $68.0 billion by 2030, according to P&S Intelligence. The industry, which generated $18.2 billion in 2019, would grow at a 12.7% CAGR between 2020 and 2030. Because genomics is a relatively new field in medical research and requires sophisticated machinery and learned professionals, it currently depends on government funding and initiatives, to prosper.

P and S Intelligence Logo

Among such efforts driving the genomics market is the 2019 decision of the Indian government to employ the Department of Biotechnology (DBT) to scan 20,000 Indian genomes, to develop better diagnostic and treatment procedures for diseases such as cancer. Similarly, the Australian government revealed its intentions in May 2018 to allocate about $377 million for a 10-year human genome project, which would accelerate research, via the integration of advanced field knowledge and technology.

Get the sample copy of this report @ https://www.psmarketresearch.com/market-analysis/genomics-market-revenue/report-sample

The COVID-19 pandemic is one of the prime reasons for the growth of the genomics market presently, as several government and private organizations are making efforts to understand the genome sequencing of infected persons. For instance, in the 2020-21 budget, the Indian government set aside $368 million for DBT and $711 million for the Council of Scientific and Industrial Research (CSIR), for genomic research.

In the coming years, the services category, on the basis of solution, will witness the fastest growth in the genomics market, as the number of such service providers is increasing around the world.

The polymerase chain reaction (PCR) division, under the technology segment, held the largest share in the genomics market in 2019. This was because of the low amplification cost while using the PCR technology, rising focus on genome research, and easier availability of this technology compared to others.

Browse report with detailed TOC on Genomics Market Research Report: By Solution (Consumables, Instruments, Services), Technology (PCR, Sequencing, Microarray), Application (Diagnostics, Drug Discovery and Development, Precision Medicine, Agriculture and Animal Research), End User (Research Centers and Academic Institutes, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies) - Global Industry Analysis and Growth Forecast to 2030 @ https://www.psmarketresearch.com/market-analysis/genomics-market-revenue

In the years to come, the precision medicine classification, under segmentation by application, is expected to experience the highest genomics market CAGR, of 13.7%. This is ascribed to the growing popularity of personalized medicine, as the effect of a disease or therapy can be different for different people. Using genomics, the prognosis of the disease can become clearer and the effects a particular therapy would have on a particular patient can be determined. This helps create a targeted therapy tailored to an individual patient, in order to better the outcome.

Make enquiry about this report @ https://www.psmarketresearch.com/send-enquiry?enquiry-url=genomics-market-revenue

The largest genomics market during 2014-2019 was North America, due to a large number of genomics projects, presence of established solution and service providers, and heavy investments by private and public organizations. In the coming years, the market would grow the fastest in Asia-Pacific (APAC), because of the increasing R&D in the field, in Japan, India, and China, owing to the heavy funding being provided by government and non-government entities.

In order to lessen the competition and consolidate their share, genomics market players are pursuing mergers and acquisitions, with the idea of:

  • Getting access to each other's R&D expertise
  • Developing more-effective drugs for rare and genetic diseases
  • Providing more information related to genes, to their customers
  • Widening their sequencing solution, oligonucleotide, and synthetic gene portfolios
  • Offering associated technology at cost-effective rates

The key players in the global genomics market are Agilent Technologies Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd. (Roche), Danaher Corporation, Quest Diagnostics Inc., QIAGEN N.V., Eurofins Scientific SE, Pacific Biosciences of California Inc., GENEWIZ Inc., Psomagen Inc., BGI Tech Solutions Co. Ltd., Oxford Nanopore Technologies Ltd., 10X Genomics Inc., and Eppendorf AG.

Related Report

Sleeping Aids Market

Sleeping aids market in North America is expected to witness significant growth, primarily due to the growing incidence of sleep disorders, technological advancements, with a rise in research and development activities; and initiatives taken by government and non-government organizations for increasing the awareness about sleep disorders and sleep hygiene.

https://www.psmarketresearch.com/market-analysis/sleeping-aids-market

Autoimmune Disease Diagnostics Market

The growing incidence and prevalence of autoimmune diseases, surging geriatric population, discovery of novel biomarkers, initiatives taken by several private and government organizations to raise awareness about autoimmune diseases, and rising strategic development activities among key players are the major factors that positively impact the growth of the global autoimmune disease diagnostics market. Due to these factors, the market is expected to generate $10,012.9 million revenue in 2030, advancing at a CAGR of 8.5% during the forecast period.

https://www.psmarketresearch.com/market-analysis/autoimmune-disease-diagnostics-market-report

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

Prajneesh Kumar
P&S Intelligence
Contact: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

Logo: https://mma.prnewswire.com/media/1224988/P_and_S_Intelligence_Logo.jpg

© 2020 PR Newswire
Nach der Korrektur – 3 Kupferproduzenten für das Comeback

Kupfer wird oft als „das Gold der Energiewende“ bezeichnet, weil es aufgrund seiner hervorragenden elektrischen Leitfähigkeit eine zentrale Rolle in vielen Technologien spielt, die für nachhaltige Energiesysteme entscheidend sind. Experten gehen aufgrund der Angebotsknappheit von einem Superzyklus aus.

Korrektur als Einstiegschance

Nach Höchstständen im Mai korrigierte das rote Metall stark. Die Abwärtsspirale verstärkte sich in den vergangenen Tagen aufgrund schwacher Konjunkturdaten aus den USA und China. Langfristig könnte sich die aktuell laufende Korrektur als exzellente Einstiegsmöglichkeit herausstellen.

3 Kupferaktien mit hohem Potential

Im neuen, kostenlosen Spezialreport stellen wir drei aussichtsreiche Unternehmen vor, die bei einem weiteren Anstieg überproportional profitieren könnten.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.